Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma

Figures & data

Figure 1. PPP1R3G was upregulated in lung adenocarcinoma (LUAD)

(a) PPP1R3G expression levels in diverse kinds of tumors. Data was extracted from The Cancer Genome Atlas (TCGA) database by TIMER.(b) PPP1R3G expression in LUAD tissues compared to that in nonmalignant lung tissues using comparison of samples in TCGA database.(c) PPP1R3G expression pre-disease and post-disease in the same patient.(d) Differential expression of PPP1R3G protein between LUAD and nonmalignant lung tissues in the CPTAC data resource.(e) PPP1R3G expression levels in LUAD tissues and normal lung tissues of mice.

Table 1. Baseline charateristics of patients with LUAD

Characteristic	Low expression of PPP1R3G	High expression of PPP1R3G	p
n	267	268
T stage, n (%)			0.076
T1	97 (18.2%)	78 (14.7%)
T2	133 (25%)	156 (29.3%)
T3	29 (5.5%)	20 (3.8%)
T4	7 (1.3%)	12 (2.3%)
N stage, n (%)			< 0.001
N0	196 (37.8%)	152 (29.3%)
N1	36 (6.9%)	59 (11.4%)
N2	26 (5%)	48 (9.2%)
N3	0 (0%)	2 (0.4%)
M stage, n (%)			0.225
M0	183 (47.4%)	178 (46.1%)
M1	9 (2.3%)	16 (4.1%)
Age, meidan (IQR)	66 (59, 72)	66 (59, 72)	0.862

Figure 2. PPP1R3G mRNA expression in clinical characteristics of lung adenocarcinoma (LUAD) tissue

(a) Differential expression of PPP1R3G mRNA between LUAD and nonmalignant lung tissues in the The Cancer Genome Atlas data resource.(b-d) Comparison of PPP1R3G mRNA expression based on patient’s gender, individual cancer, and nodal metastasis. NA P > 0.05, * P < 0.05; ** P < 0.01; *** P < 0.001.

Figure 3. Prognostic function of PPP1R3G in lung adenocarcinoma

(a) Overall survival analysis of PPP1R3G according to TCGA database.(b) Association of PPP1R3G expression with overall survival of lung adenocarcinoma patients from the UALCAN data resource.

Table 2. Univariate analysis and Multivariate analysis of the correlation of PPP1R3G expression with OS among lung adenocarcinoma

Parameter	Univariate analysis				Multivariate analysis
	HR	HR.95 L	HR.95 H	pvalue	HR	HR.95 L	HR.95 H	pvalue
age	1.00	0.98	1.02	0.84	1.01	0.99	1.03	0.36
gender	1.04	0.72	1.49	0.85	1.02	0.70	1.49	0.93
stage	1.65	1.40	1.95	2.58E-09	1.85	1.16	2.95	9.82E-3
T	1.63	1.32	2.02	8.60E-06	1.16	0.91	1.46	0.24
M	1.76	0.96	3.20	0.07	0.45	0.13	1.14	0.20
N	1.79	1.46	2.20	2.41E-08	0.98	0.66	1.45	0.91
PPP1R3G	1.90	1.48	2.43	4.17E-07	2.05	1.36	3.11	7.86E-04

Bold values indicate p < 0.05.HR,hazard ratio; CI,confidence interval.

Figure 4. The independent prognostic factor and clinical diagnostic value of PPP1R3G in lung adenocarcinoma (LUAD)

(a) Cox multivariate analysis was used to compare clinical characteristics of the forest plots of 316 patients with LUAD.(b) Receiver operating characteristic curve revealed the clinical diagnostic value of PPP1R3G in LUAD.

Figure 5. PPP1R3G relates to immune infiltration level in lung adenocarcinoma (LUAD)

(a) PPP1R3G expression was positively correlated with the infiltration levels of CD4 + T cells, macrophages, neutrophil, neutrophils, and dendritic cells in LUAD.(b) PPP1R3G CNV influences the infiltration level of B cells, CD4 + T cells, macrophages, neutrophils, and dendritic cells in LUAD.

Figure 6. Gene enrichment analysis of PPP1R3G in lung adenocarcinoma cohorts

(a-c) Enriched GO terms of PPP1R3G-linked genes.(d). Enriched KEGG cascades of PPP1R3G-related genes.(e).The PPP1R3G-miRNA regulatory network.